"Clofibric Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
| Descriptor ID |
D002995
|
| MeSH Number(s) |
D02.241.081.114.968.500.500 D02.355.726.305.500 D02.455.426.559.389.657.654.305.500
|
| Concept/Terms |
Clofibric Acid- Clofibric Acid
- Clofibrinic Acid
- p-Chlorophenoxyisobutyric Acid
- 2-(4-Chlorophenoxy)-2-methylpropionic Acid
|
Below are MeSH descriptors whose meaning is more general than "Clofibric Acid".
Below are MeSH descriptors whose meaning is more specific than "Clofibric Acid".
This graph shows the total number of publications written about "Clofibric Acid" by people in this website by year, and whether "Clofibric Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clofibric Acid" by people in Profiles.
-
Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
-
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. Cardiovasc Drugs Ther. 2009 Oct; 23(5):341-2.
-
Gemfibrozil inhibits Legionella pneumophila and Mycobacterium tuberculosis enoyl coenzyme A reductases and blocks intracellular growth of these bacteria in macrophages. J Bacteriol. 2009 Aug; 191(16):5262-71.
-
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
-
High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007 Dec 03; 100(11 A):n32-40.
-
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Am Heart Hosp J. 2007; 5(4):210-6.
-
Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
-
Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
-
Management of dyslipidemia in patients with complicated metabolic syndrome. Am J Cardiol. 2005 Aug 22; 96(4A):22E-25E.